Raras
Buscar doenças, sintomas, genes...
Distrofia miotônica de Steinert
ORPHA:273CID-10 · G71.1CID-11 · 8C71.0OMIM 160900DOENÇA RARA

A doença de Steinert, também conhecida como distrofia miotônica tipo 1, é uma doença muscular caracterizada por miotonia e por danos em múltiplos órgãos que combina vários graus de fraqueza muscular, arritmia e/ou distúrbios de condução cardíaca, catarata, danos endócrinos, distúrbios do sono e calvície.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A doença de Steinert, também conhecida como distrofia miotônica tipo 1, é uma doença muscular caracterizada por miotonia e por danos em múltiplos órgãos que combina vários graus de fraqueza muscular, arritmia e/ou distúrbios de condução cardíaca, catarata, danos endócrinos, distúrbios do sono e calvície.

Pesquisas ativas
36 ensaios
124 total registrados no ClinicalTrials.gov
Publicações científicas
39 artigos
Último publicado: 2026 Mar-Apr
Medicamentos
1 registrados
MEXILETINE

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
MEXILETINE

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
5.0
Europe
Início
Adolescent
+ adult, antenatal, childhood, infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G71.1
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
27 sintomas
💪
Músculos
22 sintomas
📏
Crescimento
14 sintomas
❤️
Coração
10 sintomas
🫃
Digestivo
9 sintomas
🫁
Pulmão
6 sintomas

+ 40 sintomas em outras categorias

Características mais comuns

100%prev.
Fraqueza muscular
90%prev.
EMG: descargas miotônicas
Muito frequente (99-80%)
90%prev.
Anormalidade da condução cardíaca
Muito frequente (99-80%)
90%prev.
Miopatia com fenômeno de aquecimento
Muito frequente (99-80%)
90%prev.
Catarata subcapsular posterior
Muito frequente (99-80%)
90%prev.
Fraqueza muscular distal
Muito frequente (99-80%)
143sintomas
Muito frequente (6)
Frequente (18)
Ocasional (69)
Muito raro (16)
Sem dados (34)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 143 características clínicas mais associadas, ordenadas por frequência.

Fraqueza muscularMuscle weakness
Muito frequente100%
EMG: descargas miotônicasEMG: myotonic discharges
Muito frequente (99-80%)90%
Anormalidade da condução cardíacaCardiac conduction abnormality
Muito frequente (99-80%)90%
Miopatia com fenômeno de aquecimentoMyotonia with warm-up phenomenon
Muito frequente (99-80%)90%
Catarata subcapsular posteriorPosterior subcapsular cataract
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico39PubMed
Últimos 10 anos12publicações
Pico20213 papers
Linha do tempo
2026Hoje · 2026🧪 1993Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

DMPKMyotonin-protein kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. May also phosphorylate PPP1R12A and inhibit the myosin phosphatase activity to regulate myosin phosphorylation. Also critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus outer membraneMitochondrion outer membraneSarcoplasmic reticulum membraneCell membraneCytoplasm, cytosolMitochondrion membrane

VIAS BIOLÓGICAS (1)
Ion homeostasis
MECANISMO DE DOENÇA

Dystrophia myotonica 1

A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Junção
258.6 TPM
Esôfago - Muscular
241.8 TPM
Artéria tibial
229.7 TPM
Aorta
207.1 TPM
Cólon sigmoide
195.1 TPM
OUTRAS DOENÇAS (6)
myotonic dystrophy type 1adult-onset Steinert myotonic dystrophylate-onset Steinert myotonic dystrophycongenital-onset Steinert myotonic dystrophy
HGNC:2933UniProt:Q09013

Medicamentos e terapias

MEXILETINEPhase 3

Mecanismo: Sodium channel alpha subunit blocker

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

204 variantes patogênicas registradas no ClinVar.

🧬 DMPK: GRCh38/hg38 19q13.31-13.32(chr19:44626066-46268105)x3 ()
🧬 DMPK: NM_004409.5(DMPK):c.253-110T>A ()
🧬 DMPK: NM_004409.5(DMPK):c.253-3C>T ()
🧬 DMPK: NM_004409.5(DMPK):c.281CAG[81] (p.Thr93_Gly94insAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAlaAla) ()
🧬 DMPK: NC_000019.9:g.46273465GCA[(49_?)] ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 218 variantes classificadas pelo ClinVar.

87
87
44
Patogênica (39.9%)
VUS (39.9%)
Benigna (20.2%)
VARIANTES MAIS SIGNIFICATIVAS
DMPK: NC_000019.9:g.46273465GCA[(49_?)] [Pathogenic]
DM1-AS: NM_004409.5(DMPK):c.*224CTG[32] [Pathogenic]
DM1-AS: NM_004409.5(DMPK):c.*224CTG[330] [Pathogenic]
DMPK: NM_004409.5(DMPK):c.*224CTG[230] [Pathogenic]
DM1-AS: NM_004409.5(DMPK):c.*224CTG[280] [Pathogenic]

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 34
2Fase 26
·Pré-clínico11
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distrofia miotônica de Steinert

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

20 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07486934 · Efficacy, Safety, and Tolerability of Zeleciment Basivarsen …Recrutando
PHASE3
NCT06716931 · Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)Recrutando
NA
NCT07505342 · Remote Assessments and Genetic Determinants of Myotonic Dyst…Recrutando
NCT07220603 · An Open-Label Extension Study of PGN-EDODM1 in People With M…Recrutando
PHASE2
NCT05481879 · Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmac…Recrutando
PHASE1, PHASE2
NCT06667453 · A Clinical Study of PGN-EDODM1 in People With Myotonic Dystr…Recrutando
PHASE2
NCT06809049 · Music Intervention for Brain-Heart Disease in Myotonic Dystr…Recrutando
NA
NCT06185764 · A Phase 1/2 Study of VX-670 in Adult Participants With Myoto…Recrutando
PHASE1, PHASE2
NCT06300307 · Study of ATX-01 in Participants With DM1Recrutando
PHASE1, PHASE2
NCT06523400 · The Efficacy and Safety of Once Daily Mexiletine PR in Patie…Recrutando
PHASE3
NCT07385443 · The Spanish National Registry for Myotonic Dystrophy Type 1Recrutando
NCT06844214 · A Study to Investigate the Safety, Tolerability, and Efficac…Recrutando
PHASE1, PHASE2
NCT05854433 · Brain Structure and Clinical Endpoints in Myotonic Dystrophy…Recrutando
NCT07362875 · Development of Quantitative Muscle Imaging as a Biomarker of…Recrutando
NCT06147414 · Development of Non-Invasive Prenatal Diagnosis for Single Ge…Recrutando
NCT07321977 · Assessment of a Portable Digital Device for Quantified Analy…Recrutando
NA
NCT06075693 · Cerebrospinal Fluid Biomarkers of Myotonic DystrophyRecrutando
NCT05020002 · Extracellular RNA Biomarkers of Myotonic DystrophyRecrutando
NCT05019625 · Biomarker Development for Muscular DystrophiesRecrutando
NCT05532813 · Evaluation of the Efficacy and Safety of Metformin in the My…Recrutando
PHASE3

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
12 papers (10 anos)
#1

A systems perspective on rare diseases: integrating human phenotype ontology with the Anukta framework of Ayurveda.

Journal of Ayurveda and integrative medicine2026 Mar 03

Rare diseases, though individually uncommon, collectively affect millions and remain among the most underdiagnosed and poorly managed conditions in conventional healthcare. Ayurveda, with its systems approach and emphasis on Dosha imbalance, offers a complementary lens to interpret such unlisted conditions, known as Anukta Vyadhi. Human Phenotype Ontology (HPO) that catalogs 10,610 phenotypes across 12,678 rare diseases can be used to bridge modern phenotype vocabularies and Ayurvedic classifications. This study explores whether integrating the Anukta framework can enable meaningful assessment of rare diseases in Ayurveda clinical settings. A curated list of 140 Nanatmaja Vikara (NV)-Vata (80), Pitta (40), and Kapha (20) was mapped to HPO terms, preserving the semantic context of Ayurvedic descriptions. Noteworthy, 128 of NV phenotypes mapped to 199 HPO terms. Over 7200 rare diseases had representation of Nanatmaja Vikara. Vata-linked features were the most enriched (4786), followed by Pitta (465) and Kapha (240). 1349 of diseases showed dual Dosha involvement and 360 of all three. Seizures, short stature, and ptosis were most prevalent features of nV; gastroesophageal reflux, fever, and abnormal skin blistering of nP; and obesity, lethargy, and pallor of nK. Detailed case interpretation of Steinert Myotonic Dystrophy, Syndromic Diarrhea and Alstrom Syndrome revealed association with Vata-Kapha, Vata-Pitta, and Tridosha features respectively. This integration of Anukta framework with structured ontologies provides a practical pathway for understanding rare diseases for management in Ayurveda clinics and integrative decision-making when biomedical options are limited.

#2

Reproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities.

Journal of medical genetics2023 Apr

Low uptake of presymptomatic testing and medically assisted reproduction in families impacted by neurogenetic diseases prompted us to investigate how reproductive options are considered and whether there is a relationship with perceived severity of the disease. We hypothesised that self-estimated severity would influence opinion on reproductive options and that prenatal/preimplantation diagnosis would be a motivation to inform relatives about their risk. We invited people impacted by neurogenetic diseases to evaluate the severity of their familial disease using analogic visual scales and to answer questionnaires about reproductive choices and intrafamilial communication. We compared answers between diseases and with the perceived severity of each disease. We analysed 562 questionnaires. Participants were impacted by Huntington disease (n=307), spinocerebellar ataxias (n=114), Steinert myotonic dystrophy (n=82) and amyotrophic lateral sclerosis/frontotemporal dementia (n=59). Self-estimated severity differed between pathologies (p<0.0001). Overall, participants considered prenatal diagnosis (78.0±34.4 out of 100) and preimplantation diagnosis (75.2±36.1 out of 100) justified more than termination of pregnancy (68.6±38.5 out of 100). They were less in favour of gamete donation (48.3±39.8 out of 100) or pregnancy abstention (43.3±40.3 out of 100). The greater the perceived severity of the disease, the more reproductive options were considered justified, except for gamete donation. Prenatal/preimplantation diagnosis was a motivation to inform relatives for only 55.3% of participants (p=0.01). Self-estimated severity minimally impacts opinions towards reproductive options. Medically assisted reproduction procedures are rarely sought and do not motivate familial communication.

#3

Long term noninvasive ventilation and continuous positive airway pressure in children with neuromuscular diseases in France.

Neuromuscular disorders : NMD2022 Dec

The aim of the study was to describe the characteristics of children with neuromuscular diseases treated with long term noninvasive ventilation or continuous positive airway pressure in France. On June 1st 2019, 387 patients (63% boys, mean age 11.2 ± 5.5 years) were treated with long term noninvasive ventilation/continuous positive airway pressure. Thirty three percent of patients had spinal muscular atrophy, 30% congenital myopathy/dystrophy, 20% Duchenne muscular dystrophy, 7% Steinert myotonic dystrophy, and 9% other neuromuscular diseases. Ninety-four percent of patients were treated with long term noninvasive ventilation and 6% with continuous positive airway pressure. Treatment was initiated electively for 85% of patients, mainly on an abnormal overnight gas exchange recording (38% of patients). Noninvasive ventilation/continuous positive airway pressure was initiated during a respiratory exacerbation in 15% of patients. Mean duration of noninvasive ventilation/continuous positive airway pressure was 3.3 ± 3.1 years. Mean objective long term noninvasive ventilation/continuous positive airway pressure use was 8.0 ± 3.1 h/24. Spinal muscular atrophy, congenital myopathy/dystrophy, and Duchenne muscular dystrophy represented 83% of children with neuromuscular diseases treated with long term noninvasive ventilation in France. Screening for nocturnal hypoventilation was satisfactory as noninvasive ventilation /continuous positive airway pressure was predominantly initiated electively.

#4

Unilateral implantation of a new non-diffractive extended range-of-vision IOL in a young patient with Curschmann-Steinert myotonic dystrophy.

American journal of ophthalmology case reports2021 Jun

We present the case of a 36-year old Curschmann-Steinert myotonic dystrophy patient with posterior subcapsular cataract that we treated with unilateral implantation of an extended depth of focus intraocular lens to address his wish for spectacle independence at far and intermediate distance. The patient underwent phacoemulsification with subsequent implantation of the AcrySof IQ Vivity IOL (Alcon, Fort Worth, TX, USA) in his left eye. Uncorrected distance visual acuity (UDVA) on the left eye increased from +0.40 logMAR preoperatively to -0.12 logMAR at 3 months postoperatively. At the three months follow-up distance corrected intermediate visual acuity (DCIVA) at 80 cm distance was -0.08 logMAR and DCIVA at 66 cm distance was 0.14 logMAR for the left eye. The defocus curve showed a functional defocus of 2.0 diopters at 0.2 logMAR or better, corresponding to the extended depth of focus. Dysphotopsia evaluation with a Halo & Glare simulator (Eyeland-Design Network GmbH, Vreden, Germany) revealed a very low level of photic phenomena. Unilateral implantation of a new generation, non-diffractive extended depth of focus IOL was well tolerated and provided good functional results for far and intermediate distances. The patient reported a very low level of photic phenomena.

#5

[Pattern macular dystrophy associated with Steinert myotonic dystrophy: A case report].

Journal francais d'ophtalmologie2021 Dec

Publicações recentes

Ver todas no PubMed

📚 EuropePMC25 artigos no totalmostrando 12

2026

A systems perspective on rare diseases: integrating human phenotype ontology with the Anukta framework of Ayurveda.

Journal of Ayurveda and integrative medicine
2022

Long term noninvasive ventilation and continuous positive airway pressure in children with neuromuscular diseases in France.

Neuromuscular disorders : NMD
2023

Reproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities.

Journal of medical genetics
2021

[Pattern macular dystrophy associated with Steinert myotonic dystrophy: A case report].

Journal francais d'ophtalmologie
2021

Unilateral implantation of a new non-diffractive extended range-of-vision IOL in a young patient with Curschmann-Steinert myotonic dystrophy.

American journal of ophthalmology case reports
2021

Levator palpebrae superioris muscle advancement for steinert myotonic dystrophy eyelid ptosis.

Journal of plastic, reconstructive &amp; aesthetic surgery : JPRAS
2019

Multiple Pilomatricomas: A Retrospective Study and Literature Review.

The American Journal of dermatopathology
2017

The relative frequency of common neuromuscular diagnoses in a reference center.

Arquivos de neuro-psiquiatria
2018

Neuromuscular diseases: Diagnosis and management.

Orthopaedics &amp; traumatology, surgery &amp; research : OTSR
2016

[Steinert myotonic dystrophy in the emergency department].

Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias
2015

[Cardiac involvement in Steinert myotonic dystrophy: Moroccan experience, about 18 cases].

The Pan African medical journal
2015

Neurotrophins, cytokines, oxidative parameters and funcionality in Progressive Muscular Dystrophies.

Anais da Academia Brasileira de Ciencias
Ver todos os 25 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distrofia miotônica de Steinert.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distrofia miotônica de Steinert

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. A systems perspective on rare diseases: integrating human phenotype ontology with the Anukta framework of Ayurveda.
    Journal of Ayurveda and integrative medicine· 2026· PMID 41780100mais citado
  2. Reproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities.
    Journal of medical genetics· 2023· PMID 36270767mais citado
  3. Long term noninvasive ventilation and continuous positive airway pressure in children with neuromuscular diseases in France.
    Neuromuscular disorders : NMD· 2022· PMID 36270935mais citado
  4. Unilateral implantation of a new non-diffractive extended range-of-vision IOL in a young patient with Curschmann-Steinert myotonic dystrophy.
    American journal of ophthalmology case reports· 2021· PMID 33997472mais citado
  5. [Pattern macular dystrophy associated with Steinert myotonic dystrophy: A case report].
    Journal francais d'ophtalmologie· 2021· PMID 34281764mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:273(Orphanet)
  2. OMIM OMIM:160900(OMIM)
  3. MONDO:0008056(MONDO)
  4. GARD:8310(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distrofia miotônica de Steinert
Compêndio · Raras BR

Distrofia miotônica de Steinert

ORPHA:273 · MONDO:0008056
Prevalência
1-5 / 10 000
Herança
Autosomal dominant
CID-10
G71.1 · Transtornos miotônicos
CID-11
Ensaios
36 ativos
Medicamentos
1 registrados
Início
Adolescent, Adult, Antenatal, Childhood, Infancy, Neonatal
Prevalência
5.0 (Europe)
MedGen
UMLS
C3250443
EuropePMC
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades